Want to see AU:ACR full AI Analyst Report?
ACR Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume88.57K
Average Volume (3M)120.95K
Market Cap
AU$6.27M
Enterprise ValueAU$8.72M
Total Cash (Recent Filing)AU$863.00K
Total Debt (Recent Filing)AU$3.63M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding522,780,330
10 Day Avg. Volume76,863
30 Day Avg. Volume120,955
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.51
Price to Sales (P/S)4.73
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$14.20M
Bulls Say, Bears Say
Bulls Say
Licensing-based Business ModelAcrux's licensing model generates royalties and milestone income while partners handle commercialization. This asset-light approach reduces capital intensity, lets the company scale revenue by extending IP into new territories, and preserves upside without large manufacturing or sales investments.
Strong Revenue Growth TrendVery large reported revenue growth indicates recent commercial traction or recognition of licensing milestones. Sustained top-line expansion, if driven by partner sales and additional licenses, supports longer-term cash generation potential and validates the commercial appeal of Acrux's topical formulations.
Very High Gross MarginA reported 100% gross margin reflects the royalty/margin nature of revenues with minimal COGS. High incremental margins create structural leverage: once fixed operating costs stabilize, additional royalty income can flow largely to the bottom line, improving long-term profitability if operating spend is controlled.
Bears Say
High Financial LeverageA 3.55 debt-to-equity ratio indicates material leverage that reduces financial flexibility. For a company with volatile royalties and milestone timing, high debt amplifies refinancing and interest risks, limits capacity for R&D or business development, and raises bankruptcy vulnerability during revenue shortfalls.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows constrain runway and force reliance on external funding or asset sales. Even with modest FCF improvement, negative operating cash to net income ratios show poor cash conversion, which undermines sustainable investment in growth or servicing of existing debt.
Ongoing Losses And Weak ProfitabilityRepeated negative profitability despite revenue gains signals structural cost or operating inefficiencies and a business not yet self-sustaining. Continued losses erode equity, pressure capital requirements, and mean future growth depends on securing external capital or achieving much higher royalty streams.
Acrux News
ACR FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is AU$6.27M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Aug 21, 2026 which is in 50 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Feb 24, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of AU$0.06 which represents an annual dividend yield of N/A. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 522,780,330 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in AU:ACR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-211.88%
Trailing 12-Months
Asset Growth
-34.57%
Trailing 12-Months
Company Description
Acrux Limited
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---